The Parkinson Progression Marker Initiative (PPMI) is a comprehensive observational,
international, multi-center study designed to identify PD progression biomarkers both to …

Purpose In this article, we discuss dynamic whole-body (DWB) positron emission
tomography (PET) as an imaging tool with significant clinical potential, in relation to …

Parkinson disease (PD) is an age-related neurodegenerative disorder that affects as many
as 1–2% of persons aged 60 years and older. With the aging of the population, the …

Multiple lines of evidence point to mitochondrial oxidative stress as a potential pathogenic
cause for Parkinson's disease (PD). MitoQ is a powerful mitochondrial antioxidant. It is …

The loss of dopaminergic neurons in the substantia nigra pars compacta leads to the
characteristic motor symptoms of Parkinson's disease: bradykinesia, rigidity and resting …

Parkinsonism is a progressive motor disease that affects 1.5 million Americans and is the
second most common neurodegenerative disease after Alzheimer's. Typical …

Background There is an urgent need for therapies that slow or reverse the progression of
Parkinson's disease (PD). Neurotrophic factors can improve the function of degenerating …

Background: In the midbrain of patients with Parkinson disease (PD), there is a selective
loss of dopaminergic neurons in the ventrolateral and caudal substantia nigra (SN). In a …

Parkinson's disease (PD) is associated with abnormal activity in spatially distributed neural
systems mediating the motor and cognitive manifestations of this disorder. Metabolic PET …

Parkinson's disease (PD) is associated with an abnormal pattern of regional brain function.
The expression of this PD-related covariance pattern (PDRP) has been used to assess …